Mediwound Net Worth

Mediwound Net Worth Breakdown

  MDWD
The net worth of Mediwound is the difference between its total assets and liabilities. Mediwound's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Mediwound's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Mediwound's net worth can be used as a measure of its financial health and stability which can help investors to decide if Mediwound is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Mediwound stock.

Mediwound Net Worth Analysis

Mediwound's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mediwound's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mediwound's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mediwound's net worth analysis. One common approach is to calculate Mediwound's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mediwound's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mediwound's net worth. This approach calculates the present value of Mediwound's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mediwound's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mediwound's net worth. This involves comparing Mediwound's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mediwound's net worth relative to its peers.

Enterprise Value

149.05 Million

To determine if Mediwound is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mediwound's net worth research are outlined below:
The company reported the previous year's revenue of 20.22 M. Net Loss for the year was (30.22 M) with profit before overhead, payroll, taxes, and interest of 2.77 M.
Mediwound currently holds about 10.41 M in cash with (13.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31.
Roughly 18.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: Is MediWound Ltd. a good long term investment - Overwhelming profit margins - jammulinksnews.com
Mediwound uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mediwound. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mediwound's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of March 2024
Upcoming Quarterly Report
View
4th of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Mediwound Target Price Consensus

Mediwound target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mediwound's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   6  Strong Buy
Most Mediwound analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mediwound stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mediwound, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Mediwound Target Price Projection

Mediwound's current and average target prices are 21.00 and 30.00, respectively. The current price of Mediwound is the price at which Mediwound is currently trading. On the other hand, Mediwound's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Mediwound Market Quote on 24th of July 2025

Low Price20.58Odds
High Price21.11Odds

21.0

Target Price

Analyst Consensus On Mediwound Target Price

Low Estimate27.3Odds
High Estimate33.3Odds

30.0

Historical Lowest Forecast  27.3 Target Price  30.0 Highest Forecast  33.3
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Mediwound and the information provided on this page.

Know Mediwound's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Mediwound is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mediwound backward and forwards among themselves. Mediwound's institutional investor refers to the entity that pools money to purchase Mediwound's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
State Street Corp2025-03-31
72.1 K
Sargent Investment Group, Llc2025-03-31
68.7 K
Ubs Group Ag2025-03-31
67.8 K
Dafna Capital Management Llc2025-03-31
64.5 K
Vanguard Group Inc2025-03-31
61.5 K
Legato Capital Management Llc2025-03-31
43.2 K
Morgan Stanley - Brokerage Accounts2025-03-31
36.6 K
Meitav Dash Investments Ltd2025-03-31
31.5 K
Charles Schwab Investment Management Inc2025-03-31
22.5 K
Investors Finance Co Plc2025-03-31
872.1 K
Yelin Lapidot Holdings Management Ltd2025-03-31
858 K
Note, although Mediwound's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Mediwound's market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 221.45 M.

Market Cap

185.25 Million

Project Mediwound's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.41)(0.43)
Return On Capital Employed(0.41)(0.43)
Return On Assets(0.41)(0.43)
Return On Equity(0.97)(1.02)
The company has Profit Margin (PM) of (1.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.32) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.32.
When accessing Mediwound's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mediwound's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mediwound's profitability and make more informed investment decisions.
Please note, the presentation of Mediwound's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mediwound's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mediwound's management manipulating its earnings.

Evaluate Mediwound's management efficiency

Mediwound has return on total asset (ROA) of (0.1988) % which means that it has lost $0.1988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7792) %, meaning that it created substantial loss on money invested by shareholders. Mediwound's management efficiency ratios could be used to measure how well Mediwound manages its routine affairs as well as how well it operates its assets and liabilities. As of July 24, 2025, Return On Tangible Assets is expected to decline to -0.43. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, Mediwound's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.29, whereas Non Currrent Assets Other are forecasted to decline to about 310.2 K.
Last ReportedProjected for Next Year
Book Value Per Share 3.13  3.59 
Tangible Book Value Per Share 3.12  3.28 
Enterprise Value Over EBITDA(6.21)(6.52)
Price Book Value Ratio 5.69  6.09 
Enterprise Value Multiple(6.21)(6.52)
Price Fair Value 5.69  6.09 
Enterprise Value174.6 M149 M
Effective management at Mediwound has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Enterprise Value Revenue
9.8688
Revenue
19.2 M
Quarterly Revenue Growth
(0.20)
Revenue Per Share
1.856
Return On Equity
(0.78)

Mediwound Corporate Filings

6K
21st of May 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
12th of May 2025
Other Reports
ViewVerify
28th of March 2025
Other Reports
ViewVerify
13A
23rd of October 2024
An amended filing to the original Schedule 13G
ViewVerify
Mediwound time-series forecasting models is one of many Mediwound's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mediwound's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Mediwound Earnings Estimation Breakdown

The calculation of Mediwound's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Mediwound is estimated to be -0.492 with the future projection ranging from a low of -0.58 to a high of -0.3225. Please be aware that this consensus of annual earnings estimates for Mediwound is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
-0.58
Lowest
Expected EPS
-0.492
-0.32
Highest

Mediwound Earnings Projection Consensus

Suppose the current estimates of Mediwound's value are higher than the current market price of the Mediwound stock. In this case, investors may conclude that Mediwound is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Mediwound's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2025Current EPS (TTM)
653.47%
0.0
-0.492
-2.05

Mediwound Earnings per Share Projection vs Actual

Actual Earning per Share of Mediwound refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Mediwound predict the company's earnings will be in the future. The higher the earnings per share of Mediwound, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Mediwound Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Mediwound, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Mediwound should always be considered in relation to other companies to make a more educated investment decision.

Mediwound Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Mediwound's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
null
nullnullnullnull
2025-05-27
2025-03-31-0.662-0.070.59289 
2025-03-19
2024-12-31-0.6075-0.360.247540 
2024-11-19
2024-09-30-0.44-0.98-0.54122 
2024-08-14
2024-06-30-0.42-0.68-0.2661 
2024-05-29
2024-03-31-0.41-1.05-0.64156 
2024-03-21
2023-12-31-0.23-0.190.0417 
2023-11-21
2023-09-30-0.44-0.240.245 
2023-08-15
2023-06-30-0.40.10.5125 
2023-05-30
2023-03-31-0.3-0.44-0.1446 
2023-03-16
2022-12-31-0.59-1.18-0.59100 
2022-11-09
2022-09-30-0.7-0.91-0.2130 
2022-08-09
2022-06-30-0.68-0.84-0.1623 
2022-05-17
2022-03-31-0.76-0.84-0.0810 
2022-03-17
2021-12-31-1.05-1.050.0
2021-11-16
2021-09-30-0.9-0.840.06
2021-08-10
2021-06-30-0.48-0.84-0.3675 
2021-05-05
2021-03-31-0.78-0.70.0810 
2021-02-25
2020-12-31-0.79-0.420.3746 
2020-11-10
2020-09-30-0.67-0.490.1826 
2020-08-06
2020-06-30-0.85-0.770.08
2020-05-20
2020-03-31-1-0.630.3737 
2020-02-25
2019-12-31-0.73-0.91-0.1824 
2019-11-14
2019-09-30-1.07-0.071.093 
2019-08-13
2019-06-30-0.193.293.481831 
2019-05-21
2019-03-31-0.97-1.05-0.08
2019-03-25
2018-12-31-1.06-0.350.7166 
2018-11-13
2018-09-30-1.37-0.770.643 
2018-08-07
2018-06-30-1.38-1.050.3323 
2018-05-10
2018-03-31-1.1-1.19-0.09
2018-03-19
2017-12-31-1.19-0.630.5647 
2017-11-16
2017-09-30-1.33-3.43-2.1157 
2017-08-03
2017-06-30-1.37-1.4-0.03
2017-05-08
2017-03-31-1.18-1.4-0.2218 
2017-02-21
2016-12-31-1.74-0.631.1163 
2016-11-14
2016-09-30-1.8-1.82-0.02
2016-07-28
2016-06-30-1.63-2.38-0.7546 
2016-04-21
2016-03-31-1.69-1.96-0.2715 
2016-01-25
2015-12-31-1.63-2.52-0.8954 
2015-10-27
2015-09-30-2.16-1.190.9744 
2015-08-03
2015-06-30-1.85-1.330.5228 
2015-05-04
2015-03-31-1.76-2.1-0.3419 
2015-02-12
2014-12-31-1.79-2.31-0.5229 
2014-11-05
2014-09-30-1.65-1.68-0.03
2014-07-31
2014-06-30-1.22-1.96-0.7460 
2014-05-02
2014-03-31-1.17-0.350.8270 

Mediwound Corporate Management

Hagit MashiachVP ResourcesProfile
CPA CPAEx DirectorProfile
Hani LuxenburgChief OfficerProfile
Pr MDCoFounder DirectorProfile
Ety MBAChief OfficerProfile
Ofer BScChief OfficerProfile
When determining whether Mediwound is a strong investment it is important to analyze Mediwound's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mediwound's future performance. For an informed investment choice regarding Mediwound Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mediwound. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
For information on how to trade Mediwound Stock refer to our How to Trade Mediwound Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mediwound. If investors know Mediwound will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mediwound listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.05)
Revenue Per Share
1.856
Quarterly Revenue Growth
(0.20)
Return On Assets
(0.20)
Return On Equity
(0.78)
The market value of Mediwound is measured differently than its book value, which is the value of Mediwound that is recorded on the company's balance sheet. Investors also form their own opinion of Mediwound's value that differs from its market value or its book value, called intrinsic value, which is Mediwound's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mediwound's market value can be influenced by many factors that don't directly affect Mediwound's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mediwound's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mediwound is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mediwound's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.